Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Pilot treatment for 13 BCR-ABL positive leukemia patients with T315I mutation].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 1 Feb 2014

Zhou Min, Sha Xinshan, Qiu Huiying, Cen Jiannong, Shen Hongjie, Sun Aining, Wu Depei

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Adolescent
Share to Aged
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BCR gene

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Pilot Projects

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Identifiers

PMID: 24606661
DOI: 10.3760/cma.j.issn.0253-2727.2014.02.022

Genes

BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Pilot treatment for 13 BCR-ABL positive leukemia patients with T315I mutation].PMID 24606661Read ↗

[BCR-ABL T315I mutant acute lymphoblastic leukemia in 3 children].Semantic proximity Read ↗

[State of the art in the treatment of chronic leukemias].Semantic proximity Read ↗

[Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with BCR-ABLT315I Mutation--Review].Semantic proximity Read ↗

Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.Semantic proximity Read ↗

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.Semantic proximity Read ↗

Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.Semantic proximity Read ↗

[Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].Semantic proximity Read ↗

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.Semantic proximity Read ↗

[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].Semantic proximity Read ↗

[Clinical significance of analysis of BCR- ABL kinase domain mutation in chronic myeloid leukemia patients].Semantic proximity Read ↗

Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.Semantic proximity Read ↗

[New therapeutic option for leukemia patients, with FLT3/Aurora kinase inhibitor, KW-2449: strategy and comparison with other kinase inhibitors].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.